Amiloride in the treatment of primary hyperaldosteronism and essential hypertension.

Article Details

Citation

Copy to clipboard

Kremer D, Boddy K, Brown JJ, Davies DL, Fraser R, Lever AF, Morton JJ, Robertson JI

Amiloride in the treatment of primary hyperaldosteronism and essential hypertension.

Clin Endocrinol (Oxf). 1977 Aug;7(2):151-7.

PubMed ID

890999 [ View in PubMed

]

Abstract

Amiloride (40 mg/day) was given to nineteen patients with primary hyperaldosteronism. There were significant falls in systolic and diastolic blood pressure, in total exchangeable sodium, and in serum sodium sodium and bicarbonate; while total exchangeable potassium, total body potassium, serum potassium, chloride and urea, and plasma renin, angiotensin II and aldosterone all increased significantly. Amiloride was effective in reducing blood pressure in patients with and without adrenocortical adenoma. No carry-over effect was seen on withdrawing amiloride. Similar changes were associated with amiloride treatment in five patients with essential hypertension; hyperkalaemia was not observed. Only negligible side-effects were encountered in the entire series of twenty-four patients.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Amiloride	Approved	Chloride	increased	Amiloride increases the level of Chloride in the blood
Amiloride	Approved	Urea	increased	Amiloride increases the level of Urea in the blood
Amiloride	Approved	Aldosterone	increased	Amiloride increases the level of Aldosterone in the blood
Amiloride	Approved	Potassium	increased	Amiloride increases the level of Potassium in the blood
Amiloride	Approved	Sodium	decreased	Amiloride decreases the level of Sodium in the blood
Amiloride	Approved	Bicarbonate	decreased	Amiloride decreases the level of Bicarbonate in the blood